With a total investment exceeding 80 million euros, LAISOLID addresses both the development of industrial processes and the creation of predictive models that relate the characteristics of the formulations to their therapeutic behavior. This approach seeks to optimize the efficacy of drugs that maintain stable levels of the active ingredient for months.
The project is also supported by collaboration with other European agents in the healthcare field, which facilitates the exchange of knowledge and coordinated progress in research. These synergies make it possible to accelerate the arrival of new therapeutic solutions for diseases that still present significant unmet medical needs.
